gentleman living kennedy disease sent me following email i remember initial trial years ago i aware researchers continued link actual study bottom message i forwarded dr fischbeck see thoughts study conversation dr fischbeck several years ago mentioned difficulty measuring results short term clinical studies sbma progresses slowly study months long i assume easier quantify results long term treatment leuprorelin spinal bulbar muscular atrophy natural history controlled study recently published new interesting study long term therapy sbma old candidate leuprorelin may know two previous phase trials leuprorelin done japan second one jasmitt study continuing treatment patients previous studies researcher group new data leuprorelin data months follow hard endpoints showed significant difference several functional scores compared drug controll maybe importantly significant difference event free survival death pneumonia similar trend risk death however significant suppose low statistical power i number patients study slow progression sbma however pneumonia important event sbma since aspiration one biggest deadly threat disease final conclusion article conclusion study showed continuous administration leuprorelin acetate appears slow progression motor deficits subjects sbma addition pneumonia free survival sbma would extended long term treatment leuprorelin acetate suggesting disease modifying effects androgen deprivation leuprorelin acetate far i know one longest controlled trial patients sbma i think may reconsider therapeutic possibilities antiandrogens i guess hear near future would nice know dr fischbeck comments important keep mind everyone talk physician first abstract article jnnp bmj content early jnnp unfortunately full text version free access note original post trial found leuprorelin